Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NTN3
UPID:
S35D1_HUMAN
Alternative names:
Solute carrier family 35 member D1; UDP-galactose transporter-related protein 7; UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter
Alternative UPACC:
Q9NTN3; A8K185; B7Z3X2; Q52LU5; Q92548
Background:
The Nucleotide sugar transporter SLC35D1, also known as Solute carrier family 35 member D1, UDP-galactose transporter-related protein 7, and UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter, plays a crucial role in the transport of nucleotide sugars across the endoplasmic reticulum membrane. This process is vital for the synthesis of glycoproteins, glycolipids, and oligosaccharides, contributing to the formation of cartilage extracellular matrix and normal skeletal development.
Therapeutic significance:
SLC35D1's involvement in Schneckenbecken dysplasia, a rare skeletal dysplasia, underscores its potential as a target for therapeutic intervention. Understanding the role of SLC35D1 could open doors to potential therapeutic strategies for skeletal dysplasias and related disorders.